It’s only a matter of time before psychedelics are approved to treat mental health issues

A $100 billion opportunity, creating monster opportunity Thursday December 09, 2021 | [View On Web]( | [Unsubscribe]( | [Report Spam](   [This Could be the World’s Next $100 Billion Bull Market](  Psychedelics could be one of the most rewarding opportunities on 2021 – and beyond.  After all, some of these drugs are being found to help treat a range of mental health issues, like obsessive-compulsive disorder, PTSD, addiction, alcoholism, depression, and anxiety.  Johns Hopkins Medicine launched the Center for Psychedelic and Consciousness Research to study compounds like LSD and psilocybin to treat a range of mental health problems, including anorexia, addiction and depression.  New York University found psilocybin mushrooms caused a “rapid and sustained” reduction in anxiety and depression in patients with cancer, as reported by the Financial Post.  [Companies are even investigating ketamine-assisted psychotherapy.](  In fact, one company’s 'Ketamine in the Reduction of Alcoholic Relapse' (KARE) psychotherapy intervention study, which was the first controlled study in the world to investigate ketamine-assisted psychotherapy, will be published in the American Journal of Psychiatry later this year.  When and if psychedelics are used more commonly to treat mental health, we could be looking at a $100 billion opportunity, creating monster opportunity.  [Click here to learn more about this opportunity.](  This message was sent to {EMAIL} on Thursday December 09, 2021.  This email is a paid advertisement. There is a very high degree of risk involved in trading. Past results are not indicative of future returns. Hugo Beau, all individuals and companies affiliated with this site assume no responsibilities for your trading and investment results. The indicators, strategies, columns, articles and all other features are for educational purposes only and should not be construed as advice. Information for any trading observations are obtained from sources believed to be reliable, but we do not warrant its completeness or accuracy, or warrant any results from the use of the information. Your use of the trading observations is entirely at your own risk and it is your sole responsibility to evaluate the accuracy, completeness and usefulness of the information. You must assess the risk of any trade with your broker and make your own independent decisions regarding any securities mentioned herein. BitFinanza - 472 Amherst St., Unit 7407271, Nashua, NH, 03063 In order to unsubscribe from this mailing list, please click [here](